Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

Hussein A. Abbas; Edward Ayoub; Hanxiao Sun; Rashmi Kanagal-Shamanna; Nicholas J. Short; Ghayas Issa; Musa Yilmaz; Sherry Pierce; Daniel Rivera; Brent Cham; Shane Wing; Ziyi Li; Danielle Hammond; Elias Jabbour; Gautam Borthakur; Guillermo Garcia-Manero; Michael Andreeff; Naval Daver; Tapan Kadia; Marina Konopleva; Courtney DiNardo; Farhad Ravandi

doi:10.1080/10428194.2022.2118533

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

Hussein A. Abbas, Edward Ayoub, Hanxiao Sun, Rashmi Kanagal-Shamanna, Nicholas J. Short, Ghayas Issa, Musa Yilmaz, Sherry Pierce, Daniel Rivera, Brent Cham, Shane Wing, Ziyi Li, Danielle Hammond, Elias Jabbour, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreeff, Naval Daver, Tapan Kadia, Marina KonoplevaCourtney DiNardo, Farhad Ravandi

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Deletions in chromosome 7 (del(7)) or its long arm (del(7q)) constitute the most common adverse cytogenetic events in acute myeloid leukemia (AML). We retrospectively analyzed 243 treatment-naive patients with AML and del(7) (168/243; 69%) or del(7q) (75/243; 31%) who did not receive any myeloid-directed therapy prior to AML diagnosis. This is the largest comprehensive clinical and molecular analysis of AML patients with del(7) and del(7q). Our results show that relapse-free survival was significantly longer for AML patients with del(7q) compared to del(7), but the overall survival and remission duration were similar. TP53 mutations and del5/5q were the most frequent co-occurring mutations and cytogenetic abnormalities, and conferred worse outcomes in del(7) and del(7q) patients. Venetoclax-based treatments were associated with worse outcomes in TP53 mutated AML patients with del(7) or del(7q), as well as del(7) with TP53 wildtype status, requiring further investigation.

Original language	English (US)
Pages (from-to)	3105-3116
Number of pages	12
Journal	Leukemia and Lymphoma
Volume	63
Issue number	13
DOIs	https://doi.org/10.1080/10428194.2022.2118533
State	Published - 2022

Keywords

AML
chr7 del
chr7q del
Myeloid leukemias and dysplasias
TP53
venetoclax

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

MD Anderson CCSG core facilities

Biostatistics Resource Group
Flow Cytometry and Cellular Imaging Facility

Access to Document

10.1080/10428194.2022.2118533

Cite this

Abbas, H. A., Ayoub, E., Sun, H., Kanagal-Shamanna, R., Short, N. J., Issa, G., Yilmaz, M., Pierce, S., Rivera, D., Cham, B., Wing, S., Li, Z., Hammond, D., Jabbour, E., Borthakur, G., Garcia-Manero, G., Andreeff, M., Daver, N., Kadia, T., ... Ravandi, F. (2022). Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leukemia and Lymphoma, 63(13), 3105-3116. https://doi.org/10.1080/10428194.2022.2118533

Abbas, HA, Ayoub, E, Sun, H, Kanagal-Shamanna, R , Short, NJ , Issa, G , Yilmaz, M, Pierce, S, Rivera, D, Cham, B, Wing, S, Li, Z , Hammond, D , Jabbour, E , Borthakur, G , Garcia-Manero, G , Andreeff, M , Daver, N , Kadia, T, Konopleva, M, DiNardo, C & Ravandi, F 2022, 'Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment', Leukemia and Lymphoma, vol. 63, no. 13, pp. 3105-3116. https://doi.org/10.1080/10428194.2022.2118533

@article{74510fec17d741e98e1496d7036a3cdd,

title = "Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment",

abstract = "Deletions in chromosome 7 (del(7)) or its long arm (del(7q)) constitute the most common adverse cytogenetic events in acute myeloid leukemia (AML). We retrospectively analyzed 243 treatment-naive patients with AML and del(7) (168/243; 69%) or del(7q) (75/243; 31%) who did not receive any myeloid-directed therapy prior to AML diagnosis. This is the largest comprehensive clinical and molecular analysis of AML patients with del(7) and del(7q). Our results show that relapse-free survival was significantly longer for AML patients with del(7q) compared to del(7), but the overall survival and remission duration were similar. TP53 mutations and del5/5q were the most frequent co-occurring mutations and cytogenetic abnormalities, and conferred worse outcomes in del(7) and del(7q) patients. Venetoclax-based treatments were associated with worse outcomes in TP53 mutated AML patients with del(7) or del(7q), as well as del(7) with TP53 wildtype status, requiring further investigation.",

keywords = "AML, chr7 del, chr7q del, Myeloid leukemias and dysplasias, TP53, venetoclax",

author = "Abbas, {Hussein A.} and Edward Ayoub and Hanxiao Sun and Rashmi Kanagal-Shamanna and Short, {Nicholas J.} and Ghayas Issa and Musa Yilmaz and Sherry Pierce and Daniel Rivera and Brent Cham and Shane Wing and Ziyi Li and Danielle Hammond and Elias Jabbour and Gautam Borthakur and Guillermo Garcia-Manero and Michael Andreeff and Naval Daver and Tapan Kadia and Marina Konopleva and Courtney DiNardo and Farhad Ravandi",

note = "Publisher Copyright: {\textcopyright} 2022 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2022",

doi = "10.1080/10428194.2022.2118533",

language = "English (US)",

volume = "63",

pages = "3105--3116",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "13",

}

TY - JOUR

T1 - Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

AU - Abbas, Hussein A.

AU - Ayoub, Edward

AU - Sun, Hanxiao

AU - Kanagal-Shamanna, Rashmi

AU - Short, Nicholas J.

AU - Issa, Ghayas

AU - Yilmaz, Musa

AU - Pierce, Sherry

AU - Rivera, Daniel

AU - Cham, Brent

AU - Wing, Shane

AU - Li, Ziyi

AU - Hammond, Danielle

AU - Jabbour, Elias

AU - Borthakur, Gautam

AU - Garcia-Manero, Guillermo

AU - Andreeff, Michael

AU - Daver, Naval

AU - Kadia, Tapan

AU - Konopleva, Marina

AU - DiNardo, Courtney

AU - Ravandi, Farhad

PY - 2022

Y1 - 2022

N2 - Deletions in chromosome 7 (del(7)) or its long arm (del(7q)) constitute the most common adverse cytogenetic events in acute myeloid leukemia (AML). We retrospectively analyzed 243 treatment-naive patients with AML and del(7) (168/243; 69%) or del(7q) (75/243; 31%) who did not receive any myeloid-directed therapy prior to AML diagnosis. This is the largest comprehensive clinical and molecular analysis of AML patients with del(7) and del(7q). Our results show that relapse-free survival was significantly longer for AML patients with del(7q) compared to del(7), but the overall survival and remission duration were similar. TP53 mutations and del5/5q were the most frequent co-occurring mutations and cytogenetic abnormalities, and conferred worse outcomes in del(7) and del(7q) patients. Venetoclax-based treatments were associated with worse outcomes in TP53 mutated AML patients with del(7) or del(7q), as well as del(7) with TP53 wildtype status, requiring further investigation.

AB - Deletions in chromosome 7 (del(7)) or its long arm (del(7q)) constitute the most common adverse cytogenetic events in acute myeloid leukemia (AML). We retrospectively analyzed 243 treatment-naive patients with AML and del(7) (168/243; 69%) or del(7q) (75/243; 31%) who did not receive any myeloid-directed therapy prior to AML diagnosis. This is the largest comprehensive clinical and molecular analysis of AML patients with del(7) and del(7q). Our results show that relapse-free survival was significantly longer for AML patients with del(7q) compared to del(7), but the overall survival and remission duration were similar. TP53 mutations and del5/5q were the most frequent co-occurring mutations and cytogenetic abnormalities, and conferred worse outcomes in del(7) and del(7q) patients. Venetoclax-based treatments were associated with worse outcomes in TP53 mutated AML patients with del(7) or del(7q), as well as del(7) with TP53 wildtype status, requiring further investigation.

KW - AML

KW - chr7 del

KW - chr7q del

KW - Myeloid leukemias and dysplasias

KW - TP53

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85138290447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138290447&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2118533

DO - 10.1080/10428194.2022.2118533

M3 - Article

C2 - 36089905

AN - SCOPUS:85138290447

SN - 1042-8194

VL - 63

SP - 3105

EP - 3116

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 13

ER -

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this